Generic Drug Development: The Complete Technical Playbook for IP Teams, R&D Leads, and Portfolio Managers
The $236 Billion Opportunity Generic drugs fill roughly 90% of all U.S. prescriptions but account for only about 22% of […]
The $236 Billion Opportunity Generic drugs fill roughly 90% of all U.S. prescriptions but account for only about 22% of […]
1. The Anatomy of a U.S. Drug Patent: Knowing the Battlefield The dominant narrative in pharmaceutical IP for most of
Chronic diseases kill 74% of all humans who die each year. That is not a warm-up statistic—it is the entire
Generic medicines fill 89% of all U.S. prescriptions yet account for only 26% of total drug spend. That ratio defines
Generic Drug Development Pitfalls: The ANDA, IP, and cGMP Playbook Analysts Actually Use Read Post »
The $400 Billion Ticking Clock: Quantifying the Patent Cliff Between 2025 and 2030, the global pharmaceutical industry faces a Loss
Executive Market Assessment: The Sovereign Paradox The Russian pharmaceutical sector currently operates within a paradigm of aggressive state-managed isolationism, creating
For pharma IP teams, portfolio managers, R&D leads, and institutional investors navigating the $300 billion patent cliff 1. The Strategic
The global pharmaceutical industry is running out of time. Between 2024 and 2030, roughly $200 billion in branded drug revenue
Pharma Licensing Deals: The Complete IP, Valuation, and Deal Structure Playbook Read Post »
1. What Patent Use Codes Are and Why They Cost the Healthcare System $3.5 Billion per Year A patent use
Get fresh news and insights, drug patent expirations & more…